Pharnext Announces the Appointment of David Horn Solomon as Chief Executive Officer

Pharnext 
Pharnext Announces the Appointment of David Horn Solomon as Chief Executive 
Officer 
 
16-Apr-2020 / 18:00 CET/CEST 
Dissemination of a French Regulatory News, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
 
*PARIS, France,**06:00 pm**, **April **16**, 2020 (CET) - *Pharnext [1] SA 
(FR0011191287 - ALPHA), an advanced clinical-stage biopharmaceutical company 
pioneering a new approach to developing innovative drug combinations based on big 
genomic data and artificial intelligence, today announced the appointment of Dr. 
David Horn Solomon as Chief Executive Officer of Pharnext, effective immediately. 
Dr. Solomon will also be proposed to join the Board of Directors at the upcoming 
Annual General Meeting. Pr. Daniel Cohen who co-founded Pharnext in 2007, will 
assume the position of Chairman of the Scientific Advisory Board. 
 
_"I am very pleased to welcome David Horn Solomon as our new CEO. David brings an 
extensive background as a biotech CEO to Pharnext and has an impressive track 
record in execution and value creation within our biotech industry. His leadership 
experience with companies in both the US and the EU makes David an ideal candidate 
to lead Pharnext into its next stage of growth." _said Michel de Rosen, Chairman 
of the Board of Directors. _"We are extremely grateful for Pr. Daniel Cohen's 
leadership and contributions to Pharnext as both founder and CEO, and we are 
excited about the opportunity to focus his outstanding expertise as the Chairman 
of the Scientific Advisory Board."_ 
 
_"I am incredibly honored to have been given the opportunity to lead Pharnext," 
_said Dr. Solomon. "Pharnext's Pleotherapy platform, by leveraging genomic 
data and artificial intelligence, offers a novel and innovative approach to 
identifying potential treatments for many indications, including rare and 
neurological disorders. I am excited to advance the clinical development of 
PXT3003 through the important upcoming Phase 3 trial in patients with 
Charcot-Marie-Tooth Disease Type 1A in the near term. I look forward to leading 
the talented team at Pharnext, and I am grateful to Daniel Cohen as a visionary 
founder, in exploring opportunities to leverage the Pleotherapy platform to 
continue to build the pipeline in other diseases of high unmet need." 
 
David Horn Solomon brings over 30 years of experience in the life sciences 
industry to Pharnext. Prior to joining Pharnext, Dr. Solomon served as Chief 
Executive Officer of Silence Therapeutics plc (LON:SLN). Earlier, he was a 
managing partner at Sund Capital, a healthcare investment fund focused on 
Nordic-based biotech opportunities. He also served as Chief Executive Officer of 
Akari Therapeutics (NASDAQ:AKRI), Bionor Pharma ASA (OSLO:BIONOR) and Zealand 
Pharma A/S (NASDAQ:ZEAL) during which time Adlixin(R), the company's lead product 
for the treatment of type II diabetes, was approved globally. Adlixin(R) is now 
marketed by Sanofi as a monotherapy and in combination with Lantus as Soliqua(R). 
Dr. Solomon was previously a member of the Board of Directors of TxCell S.A. 
(EURONXT:TXCL) (acquired by Sangamo Therapeutics, Inc.), Onxeo SA (EURONXT:ONXEO) 
and Promosome, LLC. He currently serves as Non-Executive Chairman of the Board for 
Advicenne Pharma SA (EURONXT:ADVN) and Rexgenero. Prior to joining Zealand Pharma 
A/S, Dr. Solomon headed healthcare investments at Carrot Capital Healthcare 
Ventures and served as a faculty member at the College of Physicians and Surgeons 
at Columbia University in New York in the departments of pharmacology, neurology 
and biological sciences. Dr. Solomon studied at Weill Cornell Medicine of Cornell 
University and its Graduate School of Medical Sciences where he earned his Ph.D. 
 
_"I am deeply grateful to have had the opportunity to help build Pharnext to where 
it is today. I am energized about the opportunity to dedicate more time and focus 
on my true passion, maximizing the potential of the Pleotherapy platform. In my 
role as Chairman of the Scientific Advisory Board, my efforts will be towards 
raising the awareness of Pharnext and the Pleotherapy platform and using it to 
help build a robust pipeline," _said Pr. Cohen. _"I have full confidence that 
David, a very passionate and talented leader, will provide the leadership and 
expertise needed to guide the Company through the next phases of growth. I look 
forward to working with David to drive forward Pharnext's product candidates and 
scientific platform."_ 
 
About Pharnext 
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel 
therapeutics for orphan and common neurodegenerative diseases that currently lack 
curative and/or disease-modifying treatments. Pharnext has two lead products in 
clinical development. PXT3003 completed an international Phase 3 trial with 
positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A 
and benefits from orphan drug status in Europe and the United States. PXT864 has 
generated encouraging Phase 2 results in Alzheimer's disease. Pharnext has 
developed a new drug discovery paradigm based on big genomic data and artificial 
intelligence: PLEOTHERAPY. Pharnext identifies and develops synergic 
combinations of drugs called PLEODRUG. The Company was founded by renowned 
scientists and entrepreneurs, including Professor Daniel Cohen, pioneer in modern 
genomics, and is supported by a world-class scientific team. More information at 
www.pharnext.com [2]. 
Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: 
FR0011191287). 
 
*Disclaimer* 
This press release contains certain forward-looking statements concerning Pharnext 
and its business. Such forward-looking statements are based on assumptions that 
Pharnext considers to be reasonable. However, there can be no assurance that the 
estimates contained in such forward-looking statements will be verified, which 
estimates are subject to numerous risks including the risks set forth in 
Pharnext's document de base filed with the AMF on June 2, 2016, under number 
I.016-0050 as well as in its annual periodic management reports and press releases 
(copies of which are available on www.pharnext.com) and to the development of 
economic conditions, financial markets and the markets in which Pharnext operates. 
The forward-looking statements contained in this press release are also subject to 
risks not yet known to Pharnext or not currently considered material by Pharnext. 
The occurrence of all or part of such risks could cause actual results, financial 
conditions, performance, or achievements of Pharnext to be materially different 
from such forward-looking statements. Pharnext disclaims any intention or 
obligation to publicly update or revise any forward-looking statements, whether as 
a result of new information, future events, or otherwise. 
This press release and the information that it contains do not constitute an offer 
to sell or subscribe for, or a solicitation of an offer to purchase or subscribe 
for, Pharnext shares in any country. 
 
*Contacts* 
*Pharnext* 
David Solomon 
Chief Executive 
Officer 
[e-mail] 
[3]m 
[phone] 
30 
*Media Relations (Europe)*            *Financial        *Investors**Relations 
Ulysse Communication                  Communication     (U.S.)* 
Bruno Arabian                         **(France)*       Stern Investor 
[e-mail]     Actifin           Relations, Inc. 
[phone]                  Stéphane Ruiz     Jane Urheim 
Pierre-Louis Germain                  [e-mail]  [e-mail] 
[phone]                  [phone]    [phone] 
[e-mail]    11 15 
[phone] 
 
Regulatory filing PDF file 
 
Document title: Pharnext Announces the Appointment of David Horn Solomon as Chief 
Executive Officer 
Document: https://eqs-cockpit.com/c/fncls.ssp?u=TBWGFDFLAM [4] 
1023159 16-Apr-2020 CET/CEST 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=cb3681285800d269b63272738266ab82&application_id=1023159&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=17d7eeaeab80c33fe70ecc5ba973abc0&application_id=1023159&site_id=vwd&application_name=news 
3: mailto:[e-mail] 
4: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=dfdaf732a6f8185d89b4df3b51d620db&application_id=1023159&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

April 16, 2020 12:00 ET (16:00 GMT)